Hexartan MLN 25 Tablet is a combination antihypertensive medication containing Cilnidipine 40 mg, Metoprolol Succinate 25 mg, and Telmisartan 10 mg. This formulation is designed to effectively manage hypertension by targeting multiple physiological pathways involved in blood pressure regulation. Cilnidipine, a calcium channel blocker, inhibits L-type and N-type calcium channels, leading to vasodilation and reduced peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate and myocardial contractility, thereby reducing cardiac output and oxygen demand. Telmisartan, an angiotensin II receptor blocker (ARB), prevents vasoconstriction and aldosterone secretion by blocking the AT1 receptor, contributing to blood pressure reduction and renal protection. The synergistic action of these agents provides comprehensive cardiovascular benefits, including improved arterial compliance and reduced risk of hypertensive complications such as stroke, myocardial infarction, and chronic kidney disease. Hexartan MLN 25 is indicated for patients with essential hypertension inadequately controlled by monotherapy or dual therapy. It should be used under medical supervision, considering contraindications such as severe hepatic impairment, bradycardia, or hypersensitivity to any component. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment to ensure efficacy and safety.